secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2022-09-19T23:59:59+00:00
Accession:  0001193125-22-247168
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics stockholders approve 2M share increase to 2017 Stock Incentive Plan
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2017 Stock Incentive Plan, increasing authorized shares by 2,000,000 (total 4,608,374 for new awards).
- Vote: 11,537,809 for, 8,787,318 against, 3,114,531 abstentions, 4,552,916 broker non-votes.
- Directors Patrick Vink and Frank Thomas re-elected at annual meeting on September 15, 2022.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522247168/0001193125-22-247168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522247168/d371077d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-247168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer